- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Smith & Nephew SNATS Inc(SNN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SNN
11/20/2026: SNN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Smith & Nephew SNATS Inc is a global medical technology company specializing in orthopaedics, sports medicine, and advanced wound management. The company's primary strengths lie in its established brand reputation, sticky hospital relationships, and expanding portfolio of advanced surgical robotics like the CORI system. Its core investment story centers on capturing long-term growth driven by aging demographics and rising elective procedure volumes worldwide. However, key risks include intense competition from larger medical device giants, hospital budget constraints, and potential supply chain friction. The stock suits value-oriented and dividend-conscious healthcare investors who should monitor elective surgery recovery trends and robotics adoption metrics.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While operating in structurally growing medical markets, top-line expansion tends to be moderate compared to high-beta technology sectors. |
| Momentum investor | Strong fit while signal remains positive | Short-term momentum is conditional on favorable earnings beats or positive sentiment shifts regarding elective surgery recoveries. |
| Value investor | Mixed fit | Valuation is often tied to steady healthcare demand, presenting balanced upside without deep cyclical discount characteristics. |
| Dividend investor | Strong fit | The company offers reliable dividend distributions supported by stable cash flows from established healthcare product segments. |
| Low-risk investor | Mixed fit | Although backed by essential healthcare demand, the stock remains subject to foreign exchange fluctuations, regulatory hurdles, and market volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | The stock experiences standard equity fluctuations driven by broader market sentiment and quarterly healthcare sector updates. |
| Valuation risk | Medium | Valuation multiples can compress if organic revenue growth fails to meet analyst expectations. |
| Competition risk (Stryker and Zimmer Biomet) | High | Aggressive market competition from larger orthopaedic juggernauts can pressure pricing power and market share. |
| Business quality | Strong | The company possesses durable healthcare franchises, sticky hospital customer relationships, and globally recognized brands. |
| Dividend income | Medium / high | Consistent dividend payments provide a dependable income baseline for investors seeking healthcare yield. |
| Execution risk | Medium / high | Successful execution of supply chain overhauls and new product rollouts is critical to margin improvement. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.47B USD | Price to earnings Ratio 20.29 | 1Y Target Price 33.19 |
Price to earnings Ratio 20.29 | 1Y Target Price 33.19 | ||
Volume (30-day avg) 1.4M shares | Beta 0.67 | 52 Weeks Range 26.07 - 36.11 | Updated Date 11/20/2026 |
52 Weeks Range 26.07 - 36.11 | Updated Date 11/20/2026 | ||
Dividends yield (FY) 2.66% | Basic EPS (TTM) 1.47 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Medical Devices
- BUY participation
- 33.3%
- Active BUY / eligible
- 2 / 6
- 30-Day BUY Count Change
- +2
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 18.45% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Orthopaedics | Knee and hip replacement implants, trauma fixations, and surgical robotics equipment. | Steady revenue generated from essential joint reconstruction surgeries performed globally. |
| Sports Medicine & ENT | Arthroscopic repair devices, soft tissue fixation tools, and visualization systems. | Higher-margin consumable and device sales driven by sports injuries and outpatient arthroscopic surgeries. |
| Advanced Wound Management | Advanced wound dressings, negative pressure systems, and bio-active therapy products. | Recurring institutional and home-care demand for specialized healing products addressing chronic wounds. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 20.29 | Forward PE 11.53 | Enterprise Value 15.70B | Price to Sales(TTM) 1.98 |
Enterprise Value 15.70B | Price to Sales(TTM) 1.98 | ||
Enterprise Value to Revenue 2.49 | Enterprise Value to EBITDA 9.98 | Shares Outstanding 418.11M | Shares Floating 2.11B |
Shares Outstanding 418.11M | Shares Floating 2.11B | ||
Percent Insiders 0.04 | Percent Institutions 8.72 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

